Resinco Capital Partners’ (ARS) “Buy” Rating Reiterated at Liberum Capital

Liberum Capital reiterated their buy rating on shares of Resinco Capital Partners (LON:ARS) in a report released on Thursday.

ARS traded down GBX 0.38 ($0.01) on Thursday, reaching GBX 11.88 ($0.17). 7,151,630 shares of the company traded hands, compared to its average volume of 2,270,000. Resinco Capital Partners has a 52-week low of GBX 3.62 ($0.05) and a 52-week high of GBX 15 ($0.21).

ILLEGAL ACTIVITY WARNING: “Resinco Capital Partners’ (ARS) “Buy” Rating Reiterated at Liberum Capital” was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3335888/resinco-capital-partners-ars-buy-rating-reiterated-at-liberum-capital.html.

Receive News & Ratings for Resinco Capital Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resinco Capital Partners and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

NamoCoin  Trading 16.2% Lower  Over Last Week
NamoCoin Trading 16.2% Lower Over Last Week
Brokerages Set LATAM Airlines Group  Target Price at $17.00
Brokerages Set LATAM Airlines Group Target Price at $17.00
Contrasting Walmart de M?xico y Centroam?rica  & Its Peers
Contrasting Walmart de M?xico y Centroam?rica & Its Peers
Brokerages Set Polar Capital  Target Price at $550.00
Brokerages Set Polar Capital Target Price at $550.00
Synchrony Financial  Expected to Post Quarterly Sales of $3.89 Billion
Synchrony Financial Expected to Post Quarterly Sales of $3.89 Billion
-$0.14 EPS Expected for CymaBay Therapeutics  This Quarter
-$0.14 EPS Expected for CymaBay Therapeutics This Quarter


Leave a Reply

© 2006-2018 Ticker Report. Google+.